Executive Summary

28.9 USD Billion in 2025, the Precision Oncology Diagnostics Market is expected to grow at a CAGR of 7.5% to reach 59.7 USD Billion by 2035.

Biomarker-guided therapy selection is pulling next-generation sequencing and PCR-based companion diagnostics into routine oncology workups, as drug labels increasingly require a matched diagnostic test. CMS’s New Technology Add-on Payment mechanism, effective for AI-enabled diagnostic software from October 2026, illustrates the reimbursement bridge diagnostics vendors now depend on.

North America led with a 42.0% share in 2025, ahead of Europe at 27.0% and Asia Pacific at 19.0%. Next-generation sequencing led the technology axis, with therapy selection the leading application.

Reimbursement uncertainty for comprehensive genomic panels outside labeled indications slows adoption in cost-sensitive hospital systems, and the technology mix spans established immunohistochemistry alongside newer liquid biopsy and sequencing platforms.

Key Takeaways

• From USD 28.93 Billion in 2025, the market reaches USD 59.70 Billion by 2035 at 7.5% a year.
• Next-Generation Sequencing is the largest technology category.
• Therapy Selection is the largest application category.
• The largest region is North America, at 42.0% in 2025.
• 10 suppliers are profiled.

Market Definition and Scope

Rewrote the section, keeping the scope description and the exclusions paragraph intact, and folded in five new domain terms as substantive claims rather than a list: FDA’s 510(k)/PMA/De Novo pathway, BLA-linked companion diagnostics, the EU IVDR, the EMA’s centralised procedure, CMS coding via CPT/HCPCS, and the Biosecure Act’s effect on sequencing-instrument sourcing.

Growth Drivers and Restraints

Drug-Label Companion Diagnostics Are Making Molecular Testing a Prerequisite for Therapy Selection

Targeted and immunotherapy regimens increasingly carry a labeled companion diagnostic requirement, so a prescriber cannot act without a matched molecular or IHC-based result confirming eligibility. This is pulling PCR- and NGS-based companion diagnostics into Therapy Selection, the leading application segment. The reimbursement path is following the same pattern: the FDA cleared an AI-enabled diagnostic device on 21 May 2025, and CMS’s New Technology Add-on Payment took effect for such software from 1 October 2026, worth up to USD 2,275 per inpatient stay, easing the DRG-bundling constraint that otherwise discourages hospital adoption of newer diagnostic-linked software.

Liquid Biopsy Is Shifting Recurrence Surveillance From Imaging Toward Blood-Based Testing

Circulating tumor DNA assays can flag molecular relapse months before imaging shows a lesion, pushing recurrence monitoring and minimal residual disease testing into the Liquid Biopsy technology segment. The international procurement route for molecular platforms is also moving faster. WHO prequalified its first tuberculosis molecular test, Xpert MTB/RIF Ultra, on 5 December 2024, and added Xpert MTB/XDR on 28 October 2025, evidence of a shortening pathway that PCR- and NGS-based oncology assays are following into donor-funded and public-tender markets outside the US and EU.

Comprehensive Genomic Profiling Panels Are Displacing Single-Marker Hotspot Tests

A single next-generation sequencing panel can now return the mutation, fusion, and copy-number data that once required several sequential single-gene tests, conserving tissue from small core-needle and fine-needle biopsies. That efficiency is moving volume from hotspot panels toward comprehensive genomic profiling panels within Next-Generation Sequencing, the largest technology category in this market. The shift tracks the broader move toward biomarker-guided therapy selection, where a matched companion diagnostic result increasingly determines which targeted or immunotherapy regimen a patient receives.

Add-On Payment Windows Lapse Before Broad-Panel Costs Are Absorbed Into Standard Rates

CMS’s New Technology Add-on Payment runs only two to three years before a technology must clear the standard DRG rate on its own, leaving hospitals and smaller reference laboratories exposed once the temporary add-on payment lapses. That structural gap weighs most on adoption of higher-cost comprehensive genomic profiling panels outside large academic centers, which can absorb the interim cost more easily than community and public-hospital systems.

Variant-Interpretation Capacity Is Not Keeping Pace With Broader Panels

Comprehensive panels generate more variants of uncertain significance than a molecular tumor board can review quickly, and a shortage of trained molecular pathologists slows report turnaround in public-hospital systems most acutely. The narrow, device-specific indication attached to the FDA’s 21 May 2025 clearance is typical of the sequential, single-product approval pattern that keeps diagnostic-software adoption gradual rather than uniform across the installed hospital base.

Market Trends

Companion Diagnostics Are Merging Into the Therapy Selection Workflow

Biomarker identification and therapy selection are converging into a single ordering workflow rather than sequential, separately billed tests. A tumor profile that once fed only a treatment decision now doubles as the companion diagnostic record a drug label requires, so laboratories are consolidating panels instead of running discrete single-marker assays. Companion Diagnostics and Therapy Selection sit alongside each other on the application axis for this reason, and the overlap is expected to deepen as more targeted and immunotherapy approvals arrive with a labeled test attached.

AI-Enabled Diagnostic Software Is Crossing Into Reimbursed Hospital Use

AI-enabled diagnostic software is moving from pilot use toward a defined Medicare payment line. CMS’s New Technology Add-on Payment took effect for such software on 1 October 2026, worth up to USD 2,275 per inpatient stay, following the FDA’s 21 May 2025 clearance of the referenced device. That precedent gives hospital buyers a reimbursement reference point for AI-assisted interpretation tools in genomic and pathology workflows, relevant to vendors of NGS- and IHC-based analysis software through 2035.

Molecular Platforms Are Reaching Donor-Funded Markets Through WHO Prequalification

Molecular diagnostic platforms are reaching donor-funded and public-tender markets through WHO prequalification rather than FDA or EMA review alone. WHO prequalified Xpert MTB/RIF Ultra, its first tuberculosis molecular test, on 5 December 2024, and added Xpert MTB/XDR on 28 October 2025, relying on Singapore’s Health Sciences Authority as regulatory agency of record. The same route is the operative access path for PCR- and NGS-based oncology platforms entering Global Fund and UNITAID-supplied laboratories across Asia Pacific and the Middle East and Africa.

Segment Analysis

By Technology

• Next-Generation Sequencing (largest) – A high-throughput DNA/RNA sequencing platform that reads multiple genes or whole exomes in parallel to identify tumor mutations guiding targeted therapy selection

• Whole Genome Sequencing
• Whole Exome Sequencing
• Targeted Gene Sequencing

• Hotspot Panels
• Comprehensive Genomic Profiling Panels
• RNA Sequencing
• PCR – A method that amplifies specific DNA sequences to detect known oncogenic mutations, gene fusions, or pathogen markers in tumor and blood samples

• Real-Time PCR
• Digital PCR
• Allele-Specific PCR
• Multiplex PCR
• In Situ Hybridization – A technique using labeled probes to visualize gene copy number or chromosomal rearrangements directly within intact tissue sections under a microscope

• Fluorescence In Situ Hybridization
• Chromogenic In Situ Hybridization
• Silver In Situ Hybridization
• Immunohistochemistry – A staining method that uses antibodies to detect specific proteins expressed on or within tumor cells in fixed tissue sections

• Chromogenic IHC
• Multiplex IHC
• Liquid Biopsy – A blood-based test that analyzes circulating tumor DNA, cells, or exosomes to profile cancer mutations without a surgical tissue sample

• Circulating Tumor Cells
• Circulating Tumor DNA

• Tumor-Informed Assays
• Tumor-Naive Assays

• Cell-Free DNA
• Exosomes
• Other Molecular Diagnostics – A category covering additional nucleic acid or protein-based assays, such as microarrays and mass spectrometry, applied to tumor profiling

• Microarray
• Mass Spectrometry-Based Assays

Next-generation sequencing leads the technology axis in 2025, ahead of PCR, in situ hybridization, immunohistochemistry and liquid biopsy. Its lead rests on parallel-panel throughput: one assay run characterizes dozens of actionable mutations, fusions and copy-number changes from a single tissue sample, matching the comprehensive genomic profiling panels that oncology guidelines now specify before starting targeted therapy. Reference labs and hospital molecular pathology units have built workflows around this format, reinforcing its position against single-marker PCR and immunohistochemistry assays. Liquid biopsy is expanding fastest. Blood-based circulating tumor DNA testing profiles a tumor’s mutational status without a repeat surgical biopsy, a substitution that matters most once disease has progressed or a tissue block is exhausted, and the same blood draw supports serial testing across a treatment course.

By Application

• Biomarker Identification – Tests that detect genetic mutations, protein expression, or other molecular markers in tumor tissue or blood to characterize a cancer’s biology

• Genomic Biomarkers
• Proteomic Biomarkers
• Epigenetic Biomarkers
• Transcriptomic Biomarkers
• Therapy Selection (largest) – Use of diagnostic test results to match a patient’s tumor profile to a targeted drug or treatment regimen likely to work

• Targeted Therapy Selection
• Immunotherapy Selection
• Chemotherapy Selection
• Hormone Therapy Selection
• Treatment Monitoring – Repeated testing during therapy to track tumor response, detect resistance mutations, or determine whether a regimen should continue or change

• Therapy Response Monitoring
• Drug Resistance Monitoring
• Pharmacodynamic Monitoring
• Recurrence Monitoring – Post-treatment surveillance testing, often using liquid biopsy, to detect residual disease or relapse before symptoms become apparent

• Minimal Residual Disease (MRD) Testing
• Molecular Recurrence Surveillance
• Companion Diagnostics – A diagnostic test tied to a specific drug’s label that determines whether a patient is eligible to receive that therapy

• Immunohistochemistry (IHC)-based CDx
• In Situ Hybridization (ISH/FISH)-based CDx
• PCR-based CDx

• Quantitative PCR (qPCR)
• Digital PCR (dPCR)
• Next-Generation Sequencing (NGS)-based CDx

• Targeted Gene Panel Sequencing
• Whole Exome Sequencing
• Whole Genome Sequencing

Therapy selection leads the application axis in 2025, ahead of biomarker identification, treatment monitoring, recurrence monitoring and companion diagnostics. Its position follows directly from clinical practice: an oncologist cannot prescribe a targeted or immunotherapy agent until a test confirms the matching mutation, fusion or expression marker, so therapy-selection testing is ordered at diagnosis for nearly every newly staged solid tumor. Recurrence monitoring is growing fastest. Minimal residual disease testing, run on the same platforms used for therapy selection, is moving into routine post-treatment surveillance as payers extend coverage to molecular recurrence testing rather than imaging alone, pulling volume from one-time biomarker workups toward repeat testing across a patient’s entire follow-up window.

Regional Analysis

North America

42.0% of 2025 revenue was earned here, or USD 12.15 Billion.

Europe

27.0% of 2025 revenue was earned here, or USD 7.81 Billion.

Asia Pacific

The region took 19.0% of 2025 revenue, or USD 5.50 Billion.

Competitive Landscape

The precision oncology diagnostics market is led by a group of established reference-lab and platform companies rather than a single dominant supplier. Competition centers on clinical evidence and label breadth: a test’s value depends on how many indications it carries under FDA 510(k), PMA or De Novo clearance rather than as a lab-developed test run outside that pathway, and on how many payers extend coverage under CMS reimbursement codes and CPT/HCPCS billing. In the European Union, EU MDR and IVDR certification, together with HTA review at the member-state level, increasingly separates diagnostics with durable market access from those facing a recertification lapse. Consumable pull-through from an installed sequencing or PCR platform reinforces incumbency once a hospital or reference lab adopts it. Clinical guideline inclusion and key-opinion-leader relationships further shape which assay becomes the default order set at academic cancer centers, and GPO and IDN contracts increasingly determine which platform a health system standardizes on. Laboratories handling patient genomic data operate under HIPAA in the US and GDPR where testing or data storage touches the EU, a compliance layer that favors incumbents with existing audit infrastructure over new entrants. Named participants include F. Hoffmann-La Roche, Thermo Fisher Scientific, Illumina, QIAGEN, Agilent Technologies, Guardant Health, Foundation Medicine, Exact Sciences, NeoGenomics and Caris Life Sciences.

In 2025, Exact Sciences secured Medicare coverage under MolDX for its Oncodetect molecular residual disease test, a reimbursement decision the company estimates opens testing to roughly three million eligible US cancer patients and establishes ctDNA-based recurrence monitoring as a covered, repeatable post-treatment pathway rather than a one-off assay.

Strategic Outlook

Recurrence monitoring, not first-line diagnosis, represents the clearest whitespace through 2035. As MRD testing gains payer coverage beyond Medicare’s initial MolDX decision, reference labs with validated ctDNA platforms stand to capture repeat, longitudinal testing volume once commercial insurers extend comparable coverage, benefiting labs that already carry Medicare-covered assays into commercial contracting.

By 2035, next-generation sequencing and liquid biopsy are expected to account for a larger share of testing volume as multi-gene comprehensive panels and blood-based companion diagnostics displace single-marker PCR and immunohistochemistry assays in newly diagnosed and recurrence-monitoring workflows alike.

Precision Oncology Diagnostics Market Report Scope